Bharat Biotech on May 21 said it plans to produce additional 200 million doses of COVID-19 vaccine ”Covaxin” at its subsidiary’s Gujarat-based facility, taking the overall production volume of the vaccine to about 1 billion dosages per annum.
The Hyderabad-based firm said it will utilise the Ankleshwar-based production facility of its wholly-owned subsidiary Chiron Behring Vaccines to add another 200 million doses of Covaxin.
According to a statement of Bharat Biotech, “The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety.”
Product availability at Ankleshwar will commence from the fourth quarter of 2021, said Bharat Biotech. The company has already deployed multiple production lines at its Hyderabad and Bengaluru campuses.
“This effectively takes the volumes up to 1 billion doses per annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety,” it added.